Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Analyzing the Growth Rate of the Biosimilar Therapeutic Peptides Market: What’s the Expected CAGR for the Next Decade?

In recent times, the market size of biosimilar therapeutic peptides has seen a remarkable expansion. It’s set to escalate from a worth of $2.06 billion in 2024 to an increased value of $2.68 billion in 2025, showing a compound annual growth rate (CAGR) of 30.3%. The significant growth witnessed in the historical phase can be credited to factors such as the rising requirement for affordable therapeutic solutions, supportive regulatory frameworks, patent terminations of biologic drugs, growing instances of chronic ailments, and well-set manufacturing processes.

In the coming years, the biosimilar therapeutic peptides market is forecasted to experience robust expansion. Its market value is projected to reach $4.87 billion by 2029, marking a compound annual growth rate (CAGR) of 16.1%. Several factors driving this predicted growth span from the broadening of therapeutic applications, the worldwide aging demographic, market competitiveness, to strategic alliances and collaborations, and a tilt towards non-invasive treatments by patients. Key trends for the future include development in biotechnology, a surge in demand for biological products, technological breakthroughs in the production sector, prioritization of cost-effectiveness and healthcare accessibility, and technological progression.

Which Drivers Are Expected to Have the Greatest Impact on the Biosimilar Therapeutic Peptides Market’s Growth?

The rise in the elderly population is expected to increase the number of patients suffering from chronic diseases, thereby stimulating the growth of the biosimilar therapeutic peptides market. As senior citizens are commonly susceptible to various chronic illnesses, the aging population is escalating rapidly on a global scale, and this trend is expected to persist in the foreseeable future. The World Health Organization (WHO) estimates that the global population aged 60 or above will hit 2 billion by 2050. Furthermore, the World Population Prospects report suggests a rise in the population aged 80 or older, from 143 million in 2019 to a staggering 426 million by 2050. Biosimilar therapeutic peptides, utilized in treating various chronic diseases and cancers, are expected to gain traction with the anticipated rise in the geriatric population afflicted by chronic conditions, thereby propelling the biosimilar therapeutic peptide market’s growth.

Get Your Free Sample of the Global Biosimilar Therapeutic Peptides Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=3423&type=smp

What Are the Leading Organizations Impacting the Biosimilar Therapeutic Peptides Market’s Growth?

Major companies operating in the biosimilar therapeutic peptides market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceuticals Co. Ltd., Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, BioXpress Therapeutics SA, Apotex Inc., Teva Pharmaceuticals Industries Ltd., Sandoz International GmbH, Lonza Inc., Stada Arzneimittel AG, Ipsen S.A, Biocon Biopharmaceuticals Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Alvogen Pharma US Inc., Corden Pharma GmbH, Bachem Holding AG, PolyPeptide Laboratories Ltd., PeptiDream Inc., Coherus BioSciences Inc., Celltrion Inc., BioPartners Inc., Samsung Bioepis Co. Ltd.

How Are the Latest Trends Influencing the Growth of the Biosimilar Therapeutic Peptides Market?

Leading companies in the biosimilar therapeutic peptide market are focusing on creating an advanced research platform to enhance peptide synthesis, improve production efficiency, and maintain quality consistency, right from the stage of discovery to commercialisation. The Biodrug Design Accelerator is seen as a pivotal platform to manage the research procedures involved in the discovery of peptide drugs, a field widely accepted as having great potential for innovative drug development. As an illustration, in May 2023, Fujitsu Limited, a US-based toy manufacturing and entertainment company, unveiled the Biodrug Design Accelerator platform with the aim to speed up research related to peptide drug discovery. This platform is projected to assist scientists in pharmaceutical companies involved in peptide drug discovery by enhancing the rate and efficiency of peptide drug development, particularly through the Design, Make, Test, Analyze (DMTA) cycles. This will ultimately aid in the speedy and informed creation of peptide drug candidates, whilst facilitating efficient interaction among scientists about synthesis and testing.

Get Instant Access to the Global Biosimilar Therapeutic Peptides Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

Which Key Market Segments Comprise the Biosimilar Therapeutic Peptides Market and Drive Its Revenue Growth?

The biosimilar therapeutic peptides market covered in this report is segmented –

1) By Type: Innovative, Generic

2) By Route Of Administration: Parenteral Route, Transdermal Route, Other Route Of Administrations

3) By Application: Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders

Subsegments:

1) By Innovative: Long-Acting Peptides, Combination Peptides

2) By Generic: Monoclonal Antibodies, Hormones, Enzymes

What Regions Are Leading the Charge in the Biosimilar Therapeutic Peptides Market?

The countries covered in the biosimilar therapeutic peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Key Parameters Define the Biosimilar Therapeutic Peptides Market’s Scope?

Biosimilar therapeutic peptides refer to a peptide drug that is used in place of or in addition to peptide hormones when endogenous levels tend to decline. Therapeutic peptides that are biosimilar have applications in the treatment of cancer, metabolic, pulmonary, cardiovascular, and other illnesses.

Browse Through More Similar Reports By The Business Research Company:

Anti-Hypertensive Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Oncology Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Therapeutic Dental Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/therapeutic-dental-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: